Showing 1 - 6 results of 6 for search 'Diego Malon', query time: 0.03s Refine Results
  1. 1
    <i>FGFR1</i> Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer

    <i>FGFR1</i> Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer by María Gaibar, Apolonia Novillo, Alicia Romero-Lorca, Diego Malón, Beatriz Antón, Amalia Moreno, Ana Fernández-Santander

    Published 2022-01-01
    Get full text
    Article
  2. 2
    <i>HER2</i> and <i>BARD1</i> Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment

    <i>HER2</i> and <i>BARD1</i> Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment by Apolonia Novillo, María Gaibar, Alicia Romero-Lorca, Diego Malón, Beatriz Antón, Amalia Moreno, Ana Fernández-Santander

    Published 2023-01-01
    Get full text
    Article
  3. 3
    Genetic Variants of <i>ANGPT1</i>, <i>CD39</i>, <i>FGF2</i> and <i>MMP9</i> Linked to Clinical Outcome of Bevacizumab Plus Chemotherapy for Metastatic Colorectal Cancer

    Genetic Variants of <i>ANGPT1</i>, <i>CD39</i>, <i>FGF2</i> and <i>MMP9</i> Linked to Clinical Outcome of Bevacizumab Plus Chemotherapy for Metastatic Colorectal Cancer by María Gaibar, Miguel Galán, Alicia Romero-Lorca, Beatriz Antón, Diego Malón, Amalia Moreno, Ana Fernández-Santander, Apolonia Novillo

    Published 2021-01-01
    Get full text
    Article
  4. 4
    Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition

    Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition by Miguel Quintela-Fandino, Juan V. Apala, Diego Malon, Silvana Mouron, Javier Hornedo, Lucia Gonzalez-Cortijo, Ramon Colomer, Juan Guerra

    Published 2019-05-01
    Get full text
    Article
  5. 5
    Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

    Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial by Miguel Quintela-Fandino, Esther Holgado, Luis Manso, Serafin Morales, Begoña Bermejo, Ramon Colomer, Juan V. Apala, Raquel Blanco, Manuel Muñoz, Eduardo Caleiras, Vega Iranzo, Mario Martinez, Orlando Dominguez, Javier Hornedo, Lucia Gonzalez-Cortijo, Javier Cortes, Ariadna Gasol Cudos, Diego Malon, Antonio Lopez-Alonso, María C. Moreno-Ortíz, Silvana Mouron, Santos Mañes

    Published 2020-11-01
    Get full text
    Article
  6. 6
    Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

    Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP) by Luis Manso, Cristina Hernando, María Galán, Mafalda Oliveira, Miguel A. Cabrera, Raquel Bratos, César A. Rodríguez, Manuel Ruiz-Borrego, Salvador Blanch, Antonio Llombart-Cussac, Juan I. Delgado-Mingorance, Iñaki Álvarez-Busto, Isabel Gallegos, Lucía González-Cortijo, Serafín Morales, Elena Aguirre, Blanca A. Hernando, Ana Ballesteros, José E. Alés-Martínez, Cristina Reboredo, Amparo Oltra, María González-Cao, Marta Santisteban, Diego Malón, Isabel Echeverría, Elisa García-Garre, Estela Vega, Sònia Servitja, Raquel Andrés, Carlos E. Robles, Rafael López, Elena Galve, María J. Echarri, Marta Legeren, Fernando Moreno

    Published 2020-12-01
    Get full text
    Article

Search Tools: